Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study
-
Published:2024-06
Issue:6
Volume:47
Page:553-561
-
ISSN:2444-3824
-
Container-title:Gastroenterología y Hepatología (English Edition)
-
language:en
-
Short-container-title:Gastroenterología y Hepatología (English Edition)
Author:
Serrano Díaz Lidia,
Iniesta Navalón CarlesORCID,
Gómez Espín Rosa,
Nicolás De Prado Isabel,
Bernal Morell Enrique,
Rentero Redondo Lorena
Reference30 articles.
1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer Stephen;Lancet,2002
2. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005
3. Progress with infliximab biosimilars for inflammatory bowel disease;Kurti;Expert Opin Biol Ther,2018
4. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort;Gonczi;Inflamm Bowel Dis,2017
5. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study;Park;Ann Rheum Dis,2013